Clearside Biomedical Inc expected to post a loss of 10 cents a share - Earnings Preview

Clearside Biomedical,

25/03/2025 20:43

Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a fall in quarterly revenue when it reports  results on March 27 for the period ending December 31 2024

The Alpharetta Georgia-based  company is expected to report a 97.2% decrease in revenue to $176.67 thousand from $6.35 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Clearside Biomedical Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Clearside Biomedical Inc is $6.00​, above​ its last closing price of $1.03. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.12
-0.10
Beat
19.5
Jun. 30 2024
-0.13
-0.13
-0.10
Beat
25.9
Mar. 31 2024
-0.14
-0.14
-0.15
Missed
-9​
Dec. 31 2023
-0.08
-0.09
-0.08
Beat
8.6
​​Sep. 30 2023
-0.16
-0.15
-0.15
Met
3.2
Jun. 30 2023
-0.14
-0.14
-0.15
Missed
-5.9​
Mar. 31 2023
-0.14
-0.14
-0.15
Missed
-7.1
Dec. 31 2022
-0.13
-0.13
-0.16
Missed
-27

This summary was machine generated March 25 at 20:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)